1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1646
  6. Examiner Holtzman

Examiner Holtzman Katherine A

1646-HOLTZMAN-KATHERINE-A

Employment Information

Art Unit:1646 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
436 — Chemistry: analytical and immunological testing
Phone:(571) 270-0252
Email:None
Location:None
Title:Pat Examnr Indl Engrg
Service:3 years
Grade:GS-09

Grant Rate and Difficulty Ranking

90
3-Year Grant rate: 29% over 17 cases
Difficulty: Very Hard
Difficulty Percentile: 90th

With Examiner Holtzman, you have a 29% chance of getting an issued patent by 3 years after the first office action. Examiner Holtzman is a very hard examiner and in the 90th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Holtzman, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1646

Examiner Holtzman's grant rate is lower than that of Art Unit 1646 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Holtzman 1.7
Art Unit 1646 1.5

Interview Benefit

Grant Rate without Interview

Examiner Holtzman has granted 3 of 14 cases without any applicant-requested interviews for a grant rate of 21%.

Grant Rate with Interview

Examiner Holtzman has granted 2 of 3 cases with at least one applicant-requested interview for a grant rate of 67%.

Interview Benefit

With Examiner Holtzman, conducting an interview increases your chance of getting a patent granted by 219%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17601831 Therapeutic Agent For Urological Cancer Which Is Characterized By Being Administered With Il-6 Inhibitor And Ccr2 Inhibitor In Combination Rejection information available with a Premium Stats subscription. See our pricing. Patented View
17999387 Potent Neutralizing Antibodies Against Sars-Cov-2, Generation And Uses Thereof Abandoned View
17996403 Antibody Against Nectin-4 And Application Thereof Patented View
17887444 Ipsc-Based Vaccine As A Prophylactic And Therapeutic Treatment For Cancer Abandoned View
17418624 Fgf21 Variant Polypeptide Molecules And Application Thereof Patented View
19064325 Cd4+ T Cells Expressing Il-10 And Chimeric Antigen Receptors And Uses Thereof Patented View
17161772 Aluminum Based Adjuvants For Tolerogenic Vaccination Patented View
17255653 Compositions And Methods For Treating Inflammasome Related Diseases Or Conditions Patented View
18635426 Antibodies For Il-17c Abandoned View
17103347 Cationic Liposomes For Cancer Immunotherapy Abandoned View
17055792 Protein Binding Nkg2d, Cd16 And A Fibroblast Activation Protein Abandoned View
16975512 Methods And Materials For Treating Cancer Patented View
17612564 Anti-Pd-L1 Antibody, And Preparation Method Therefor And Application Thereof Patented View
17906898 Antibodies Binding Cd40 And Uses Thereof Patented View
19073422 Cd142 Antibodies, Antibody-Drug Conjugates, Preparations And Uses Thereof Patented View
17790937 Anti-Gitr Antibodies And Uses Thereof Abandoned View
17143587 Methods And Compositions For Reducing Immunogenicity By Non-Depletional B Cell Inhibitors Abandoned View
17821664 Compositions And Methods For T Cell Engineering Patented View
17612514 Mmp-9 Antibodies And Methods Of Use Thereof Abandoned View
17299428 Pks-Island Positive E. Coli As Marker Of Negative Response To Anti-Pd1 Therapy In Colorectal Cancer Patented View
17259969 Ox-40 Agonist, Pd-1 Pathway Inhibitor And Ctla-4 Inhibitor Combination For Use In A Method Of Treating A Cancer Or A Solid Tumor Abandoned View
17612286 Treating Chronic Liver Disease Abandoned View
17607631 Antibodies Binding To Plasmodium Circumsporozoite Protein And Uses Thereof Abandoned View
17766597 Antibodies Having Specificity For Nectin-4 And Uses Thereof Patented View
17266349 Multi-Specific Binding Proteins That Bind Bcma, Nkg2d And Cd16, And Methods Of Use Patented View
17432819 Method And Composition For Predicting Long-Term Survival In Cancer Immunotherapy Abandoned View
18272337 Protocol To Minimize Calcineurin Inhibitor Nephrotoxicity Abandoned View
17435380 Anti-Sirp-Alpha Antibodies Abandoned View
16982762 Method Of Treating Asthma Patented View
16969740 Engineered Nanovesicles As Checkpoint Blockade For Cancer Immunotherapy Abandoned View
17275986 Bispecific Antibody Targeting Il-1r1 And Nlpr3 Patented View
18570249 Anti-Pdl1 Antibodies And Uses Thereof Abandoned View
17439945 Aqueous Formulations Of Tnf-Alpha Antibodies In High Concentrations Abandoned View
18618634 Methods Of Treating Complement-Mediated Disease Patented View
17480946 Treatment Of Non-Alcoholic Steatohepatitis (Nash) With Il-27 Antibody Patented View
18792921 Ige Binding Proteins And Uses Thereof Patented View
17280035 Combination Of A Pd-1 Antagonist, An Atr Inhibitor And A Platinating Agent For The Treatment Of Cancer Patented View
17275995 Bispecific Antibody Targeting Il-1r1 And Nlpr3 Patented View
16804882 Eosinophils Alleviate Lung Allograft Rejection Through Their Modulation Of Cd8+ T Cells Patented View
17286759 Anti-Cd79b Antibodies, Drug Conjugates, And Applications Thereof Patented View
17267157 Anti-Il1rap Antibody Compositions Patented View
17565942 Fusion Proteins Comprising A Binding Protein And An Interleukin-15 Polypeptide Having A Reduced Affinity For Il15ra And Therapeutic Uses Thereof Abandoned View
16622259 Targeted Hd5 Antibody And Assay Methods For Diagnosing And Treating Inflammatory Bowel Disease Patented View
17277511 Anti-Human Cd45rc Antibodies And Uses Thereof Patented View
17204526 Genetically Modified Major Histocompatibility Complex Mice Abandoned View
18210250 Nanocomposite Including Abscisic Acid-Loaded Collagen Nanoparticles Patented View
17475753 Early Detection Marker For Degenerative Osteoarthritis With Trim24-Rip3 Axis Patented View
17130975 Fusion Proteins Comprising A Binding Protein And An Interleukin-15 Polypeptide Having A Reduced Affinity For Il15ra And Therapeutic Uses Thereof Abandoned View
17511183 Treatment Of Cancers With Gm-Csf Antagonists Abandoned View
17817845 Treatment With A Bispecific Antibody That Binds Ctla4 And Pd1 Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.